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Abstract
Background: It is well known that a low skeletal muscle mass (SMM) is associated with stroke. However, it is
unknown whether increasing muscle mass can prevent stroke.
Methods: This community-based cross-sectional study was supported by the regional government. SMM
measurements and brain computed tomography was performed in 722 stroke-free and dementia-free subjects
(aged 50–75 years). Subjects were divided into quartiles (Q) by SMM, checked using the bioelectrical impedance
analysis method (InBody 770, InBody, Seoul, Korea). Odds ratios (ORs) of brain white matter changes/silent infarction
(WMC/SI) were calculated. The subjects were then divided into two groups by sex and evaluated.
Results: In the analysis of the four groups, the unadjusted ORs of Q2–Q4 were 0.616 (95% confidence interval
[CI], 0.372–1.022; P = 0.061), 0.290 (CI, 0.159–0.530; P < 0.001), and 0.209 (CI, 0.108–0.403; P < 0.001) for the risk of
WMC/SI. Adjusted ORs for age, hypertension, diabetes mellitus, education, hypercholesterolemia, and smoking
were 0.994 (CI, 0.513–1.740; P = 0.085), 0.669 (CI, 0.329–1.362; P = 0.268), and 0.464 (CI, 0.219–0.984; P = 0.045). In
the two–group (dichotomized) analysis, the unadjusted OR for the higher muscle mass groups (Q3 + Q4) was
0.313 (CI, 0.200–0.491; P < 0.001). The adjusted OR was 0.577 (CI, 0.340–0.979; P = 0.042). Considering sex, the
adjusted OR were 0.351 (CI, 0.141–0.869; P = 0.024) in men and 0.771 (CI, 0.391–1.519; P = 0.452) in women.
Conclusions: Our findings suggest that increased SMM may protect against WMC/SI, especially in men.
Keywords: Sarcopenia, Body composition, Skeletal muscle mass, Risk factor, Stroke, Bioelectrical impedance
analysis (BIA)
Background
Since Rosenberg first used the term “sarcopenia,” which
refers to the involuntary loss of skeletal muscle mass
(SMM) followed by strength [1, 2], it has been known as
a risk factor for cardiovascular disease [3, 4].
We have shifted from the idea that sarcopenia is the
risk factor for stroke to amount of skeletal muscle is
preventive factor for stroke.
It is well known that chronic low grade inflammation
cause atherosclerosis. The recent findings allow the
skeletal muscle to be considered as an endocrine organ
[5]. Contraction of skeletal muscle secret myokines and
block the inflammatory signaling pathways generated by
chronically elevated levels of pro-inflammatory adipokines
[6] Muscle mass can be increased by weight training exer-
cise. However, it is unknown whether increased muscle
mass can prevent stroke. One study showed that increasing
muscle strength in adolescent men had a decreased risk of
later cardiovascular events in middle age [7]. Thus, we
hypothesized that increased SMM can prevent stroke after
middle age.
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Stroke itself can cause sarcopenia [8, 9]. So skeletal
muscle data after stroke might be contaminated by stroke
itself. Thus, is important to collect skeletal muscle data
before stroke occurs. Brain white matter changes/silent
infarction (WMC/SI) represents an independent risk
factor for cerebral infarction [10, 11]. Our study inves-
tigated the correlation between SMM and WMC/SI in
a community-based setting.
Methods
We have brought data from the Prevention of Stroke
and Dementia (PRESENT) project, supported by the
regional government that was initiated in July 2007.
The primary goal of the PRESENT project is to prevent
stroke and dementia using public education efforts,
public relations, early medical check-ups, and research
in Ansan City, Gyeonggi-do, Korea [12].
Stroke and dementia-free adults (aged 50–75 years)
in Ansan City (The population of Ansan is 744,356;
Dec.31,2016), were recruited between 2007 and 2009 by
systemic random sampling using a previously described
method (Fig. 1) [12]. All of the procedures were performed
after written permission was obtained from each subject.
Of the 780 subjects, we excluded those for whom some
were missing (education level data; 54 subjects, SMM
data; 4). Finally, 722 subjects were evaluated. Stroke
history was screened by self-report and dementia was
screened by mini mental state examination.
1. Risk factor assessment
Trained nurses and neurologists did personal inter-
views and evaluations Education, hypertension, smoking,
diabetes mellitus, and hypercholesterolemia data were
chyecked. Blood pressure was measured. Blood chemistry
data were analysed. Hypertension was defined as a previ-
ous diagnosis of hypertension, the use of one or more
anti-hypertensive drugs, a systolic pressure ≥ 140 mmHg,
or a diastolic pressure ≥ 90 mmHg [13]. Hypercholesterol-
emia was defined as the use of one or more lipid lowering
agents, a fasting total cholesterol level ≥ 240 mg/dL, a
low-density lipoprotein cholesterol level ≥ 160 mg/dL,
or a triglyceride level ≥ 200 mg/dL [14]. A participant
was said to have diabetes mellitus if he/she had a previ-
ous diagnosis of diabetes mellitus, used anti-diabetic
medication (including insulin), or had a fasting glucose
level ≥ 126 mg/dL [15]. Smoking was defined as a current
smoking habit.
2. Neuroimaging
We used a Brilliance™ CT Scanner (six slices; Philips,
Eindhoven, the Netherlands) for brain computed
Fig. 1 Flow chart of study participants
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tomography (CT). Two different neurologists blinded to
the participants’ clinical conditions independently evalu-
ated the results and laboratory findings as previously de-
scribed [12]. The subjects were divided into the normal
and WMC/SI groups according to the brain CT findings.
The WMC/SI group included participants with WMC,
SI, or both. SI was defined as well-defined areas > 2 mm
showing attenuation without a relevant clinical neurological
event. WMC was defined as ill-defined and moderately
hypodense areas of >5 mm located in the periventricular or
subcortical area, including extensive periventricular lesions
and severe leukoencephalopathy [16, 17].
3. Measurement of skeletal muscle mass
SMM was measured by using an InBody720 body
composition analyser (InBody, Seoul, Korea). The validity
of this bioelectrical impedance analysis was documented
in previous studies [18–20]. Subjects were divided into
four quartiles (Q) based on their SMM using the 25th,
50th, and 75th percentiles. We separately applied the
reference points because men tend to have greater SMM
than women.
4. Data analyses
We used a multiple regression analysis to obtain odds
ratios (ORs) [10] and unadjusted and adjusted ORs [21].
First, the independent variable was the four SMM quar-
tiles. Well-known risk factors for WMC/SI, including
age, hypertension, education, diabetes mellitus (DM),
hyperlipidaemia, and current smoking status, were used
as covariates. Next, the subjects were dichotomized into
a high muscle mass group (HMMG, Q3 and Q4) and a
low muscle mass group (LMMG, Q1 and Q2) because
Q2 was not significant on univariate analysis when Q1
was used as a reference. Men and women were analysed
separately. We used two-tailed P values for all analyses.
The analyses were performed using SPSS for Windows,
version 18 (SPSS Inc., Chicago, IL, USA). Significance
was set at values of P < 0.05.
Results
The baseline data for the 722 subjects enrolled in this
study are summarized in Table 1. The subjects in the
WMC/SI group were older, had a higher incidence of
hypertension and DM, and had lower education levels
compared to the normal brain CT group (Table 1). The
mean SMM of each quartile is shown in Table 2.
In normal CT subjects, the muscle mass groups were
equally distributed (Q1 20.9%, Q2 24.3%, Q3 26.6%, Q4
28.2%, Q1 +Q2 45.2%, Q3 + Q4 54.8%). However, >70%
of subjects in the WMC/SI group were in the lower
muscle mass subgroup (Q1 42.2%, Q2 30.3%, Q3 15.6%,
Q4 11.9%, Q1 + Q2 72.5%, Q3 +Q4 27.5%) (Table 2). In
the quartile analysis, unadjusted analysis showed that
the ORs for WMC/SI for each quartile (reference, Q1)
were 0.616 (95% confidence interval [CI], 0.372–1.022,
P = 0.061) in Q2, 0.029 (95% CI, 0.159–0. 53; P < 0.001)
in Q3 and 0.209 (95% CI, 0.108–0.403; P < 0.001) in Q4.
After adjustment for age, hypertension, DM, education,
hypercholesterolemia, and smoking, the ORs for WMC/
SI for each quartile (reference, Q1) were 0.944 (95% CI,
0.513–1.742; P =0.854) in Q2, 0.669 (95% CI 0.329–
1.362, P = 0.268) in Q3 and 0.046 (95% CI, 0.219–0.984;
P = 0.045) in Q4.
In the dichotomized analysis, the unadjusted analysis
showed that the ORs for WMC/SI for the HMMG were
0.313 (95% CI, 0.200–0.491; P < 0.001). After adjustment
for age, hypertension, DM, education, hypercholesterol-
emia, and smoking, the ORs for WMC/SI for HMMG
were 0.577 (95% CI, 0.341–0.979; P = 0.042). After men
and women were divided by sex, the adjustment ORs
were 0.351 (95% CI, 0.141–0.0869; P = 0.024) in men
and 0.771 (95% CI, 0.391–1.519; P = 0.452) in women
(Fig. 2).







Mean age, years (SD) 58.5 (7.1) 68 (7.8) 0.000
Men, n (%) 276 (45) 45 (41.3) 0.469
Mean education, years (SD) 9.6 (4.4) 7.5 (5.1) 0.000
Hypertension, n (%) 307 (50.1) 94 (86.2) 0.000
Diabetes mellitus, n (%) 103 (16.8) 34 (36.7) 0.000
Hypercholesterolemia, n (%) 199 (32.5) 40 (36.7) 0.387
Current smoking, n (%) 106 (17.3) 19 (17.4) 0972
Mean skeletal muscle mass, kg (SD) 24.4 (9.6) 22.0 (5.0) 0.011
Skeletal muscle mass, Q
Q1, n (%) 128 (20.9) 46 (42.2)
Q2, n (%) 149 (24.3) 33 (30.3)
Q3, n (%) 163 (26.2) 17 (15.6)
Q4, N (5) 173 (28.2) 13 (11.9)
Table 2 Skeletal muscle mass by quartile
Quartile Skeletal muscle mass, kg
Men Women
1 (0–25th percentile) <26 <18.3
2 (26th–50th percentile) 26–28.1 18.3–20
3 (51st–75th percentile) 28.1–30.7 20–21.6
4 (76th–100th percentile) >30.7 >21.6
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Discussion
Long term exercise prevents cardiovascular risk factor
by secret various anti-inflammatory myokine by skeletal
muscle [22]. There are two ways to increasing anti-
inflammatory myokines by skeletal muscle, increasing
physical activity and increasing muscle mass.
Our data showed that individuals in the high HMMG
displayed fewer WMC/SI areas on the brain CT. Consid-
ering that WMC/SI of the brain is closely correlated with
further cerebral infarction [10, 11], we can hypothesize
that men in the HMMG had a lower risk of cerebral in-
farction. Furthermore, we hypothesize that increasing
SMM by exercise maybe associated with protection of
cerebrovascular dieseases.
In the unadjusted and adjusted analyses, we detected a
trend of a protective effect of higher SMM for cerebral
vascular lesions. The dichotomized analysis also showed
a significant protective effect on HMMG. When we di-
vided the subjects by sex, the protective effect of a high
SMM against stroke was observed only in men (Fig. 2).
Because diabetes mellitus, hypertension, hypercholester-
olemia and SMM, there are difference in data before and
after adjustment.
The protective effect of increased SMM against stroke
risk was apparent in men. We cannot explain this
phenomenon; a previous study also demonstrated the
protective effect of muscle strength only in men [7]. Al-
though women did not demonstrate a negative effect of
increased muscle mass, they were excluded from that
study. We believe that this is due to the difference in
muscle composition ratios. It is known that many muscle
parameters such as fat free mass, SMM, and skeletal
muscle index are related to sex. Or absolute HSMG has
protective effect. Men in Q1 had a higher absolute SMM
than women in Q4 (Table 2).
An individual’s SMM peaks at 24 years of age and is
maintained quite well throughout the fifth decade with
a moderate decline of about 10% [23]. The SMM then
decreases up to 40% between ages 50 and 80 years [24].
Therefore, we recruited subjects > 50 years of age for
the current study.
No gold standard exists to assess SMM. Dual-energy
X-ray absorptiometry (DEXA) can be used to assess
SMM [25], but a DEXA scanner is a fixed and expensive
piece of equipment that utilizes ionized radiation. By
comparison, eight-polar bioelectrical impedance analysis
(BIA, using the InBody720, for example) is a simple and
inexpensive method whose results correlate well with
those of DEXA [20]. High SMM may secondary effect of
long term exercise. But this fact is not important. In BIA
era, SMM is simple, repeatable and objective biomarker.
We did not use an index that divided SMM by other
parameters such as height or body surface area. It would
be appropriate to use such an index rather than an abso-
lute value. However, Rantandem et al. demonstrated that
muscle strength itself was an independent risk factor of
mortality regardless of body mass index [26]. Height is
used in an algorithm for calculating SMM by bioelec-
trical impedance analysis. The exact algorithm used by
the InBody system is not disclosed. Therefore, dividing
SMM by height is not appropriate.
According to the current guidelines for the primary
prevention of stroke, obesity is a well-known modifiable
risk factor for stroke. However, in the previous versions
of the guideline available when the PRESENT project
was designed, obesity was a less well-documented risk
factor. Therefore, we did not include obesity data in this
study [21]. This is a limitation of our study.
This was a cross-sectional rather than prospective
study. We included stroke- and dementia-free subjects
who could visit city health centers by walking. A brain
CT was performed at the same time as the SMM assess-
ment. We believed that the study’s cross-sectional design
could eliminate the long-term indirect effect of exercise.
Preserved muscle fitness in obesity may not only prevent
sarcopaenic obesity but also decrease associated risks for
metabolic syndrome and early mortality [27].
We do not measure inflammatory cytokine such as
IL-6,10. This is one of major limitation of this study.
Conclusions
This study findings suggest that increased SMM may be
associated with a protective effect against WMC/SI in
community-dwelling men without stroke or dementia.
Regular weight training exercises to increase SMM may
help prevent stroke.
Fig. 2 Odds ratios of the each muscle mass group for white matter
change/silent infarction on brain computed tomography (reference,
quartile 1 [Q1] or D1). Adjusted for age, education, hypertension,
diabetes mellitus, and current smoking. Q1, 1st-25th percentile group;
Q2, 26th-50th percentile group; Q3, 51st-75th percentile group;
Q4, 76th-100th percentile group; D1, 1st -50th percentile group;
D2, 51st-100th percentile group
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